Cellebrite DI Ltd.
Cellebrite DI Ltd. Fundamental Analysis
Cellebrite DI Ltd. (CLBT) shows moderate financial fundamentals with a PE ratio of 44.96, profit margin of 16.47%, and ROE of 18.39%. The company generates $0.4B in annual revenue with strong year-over-year growth of 23.41%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 79.0/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze CLBT's fundamental strength across five key dimensions:
Efficiency Score
WeakCLBT struggles to generate sufficient returns from assets.
Valuation Score
WeakCLBT trades at a premium to fair value.
Growth Score
ModerateCLBT shows steady but slowing expansion.
Financial Health Score
ExcellentCLBT maintains a strong and stable balance sheet.
Profitability Score
ExcellentCLBT achieves industry-leading margins.
Key Financial Metrics
Is CLBT Expensive or Cheap?
P/E Ratio
CLBT trades at 44.96 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, CLBT's PEG of 13.94 indicates potential overvaluation.
Price to Book
The market values Cellebrite DI Ltd. at 7.27 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 39.94 times EBITDA. This signals the market has high growth expectations.
How Well Does CLBT Make Money?
Net Profit Margin
For every $100 in sales, Cellebrite DI Ltd. keeps $16.47 as profit after all expenses.
Operating Margin
Core operations generate 13.98 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $18.39 in profit for every $100 of shareholder equity.
ROA
Cellebrite DI Ltd. generates $8.34 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Cellebrite DI Ltd. generates strong operating cash flow of $159.64M, reflecting robust business health.
Free Cash Flow
Cellebrite DI Ltd. generates strong free cash flow of $147.47M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.60 in free cash annually.
FCF Yield
CLBT converts 4.96% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
44.96
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
13.94
vs 25 benchmark
P/B Ratio
Price to book value ratio
7.27
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.81
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.05
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.56
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.18
vs 25 benchmark
ROA
Return on assets percentage
0.08
vs 25 benchmark
ROCE
Return on capital employed
0.12
vs 25 benchmark
How CLBT Stacks Against Its Sector Peers
| Metric | CLBT Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 44.96 | 35.19 | Worse (Expensive) |
| ROE | 18.39% | 1155.00% | Weak |
| Net Margin | 16.47% | -127067.00% (disorted) | Strong |
| Debt/Equity | 0.05 | 0.41 | Strong (Low Leverage) |
| Current Ratio | 1.56 | 4.71 | Neutral |
| ROA | 8.34% | -314918.00% (disorted) | Weak |
CLBT outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Cellebrite DI Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
108.60%
Industry Style: Growth, Innovation, High Beta
High GrowthEPS CAGR
-13379.43%
Industry Style: Growth, Innovation, High Beta
DecliningFCF CAGR
632.03%
Industry Style: Growth, Innovation, High Beta
High Growth